What clinical trials are currently recruiting to test ivermectin or fenbendazole with chemotherapy?

1. The single clear recruiting program: ivermectin + immunotherapy in metastatic TNBC

The clearest and repeatedly cited trial currently recruiting is the phase I/II study NCT05318469 (often described in coverage as ivermectin combined with balstilimab or pembrolizumab for metastatic triple‑negative breast cancer), which has reported dosing schedules and early safety/clinical benefit observations and was presented at major meetings as ongoing and recruiting with an expected finish around 2026 if enrollment and follow‑up proceed as planned ^{[1] [5] [2] [3]}.

2. Other registered or promoted studies: fragmentary signals, not solid recruiting lists

Some outlets and clinic pages list additional programs or “trials” testing antiparasitics (including ivermectin) broadly in advanced or metastatic cancers — for example, a Frank Arguello Cancer Clinic protocol testing a portfolio of FDA‑approved antibacterial, antifungal and antiparasitic drugs — but these descriptions are clinic‑level reports and do not clearly map to independently confirmed, actively recruiting ClinicalTrials.gov entries for ivermectin or fenbendazole paired with conventional chemotherapy ^{[6] [4]}.

3. Fenbendazole: no recruiting chemotherapy combination trials documented in registries or peer‑reviewed summaries

Despite widespread patient interest and extensive online compilations of case reports, fenbendazole has not been documented in the reviewed sources as the subject of a registered, actively recruiting trial that pairs it with standard chemotherapy for human cancers; the literature and trial searches referenced in these reports instead emphasize preclinical activity and anecdotal case series, with mebendazole (a related benzimidazole) having the bulk of human trial experience among benzimidazoles ^{[4] [2] [7] [8]}.

4. Why the record is sparse and what that means for patients and clinicians

Multiple reviews and oncology investigators stress that the evidence for ivermectin and benzimidazoles in cancer is overwhelmingly preclinical and anecdotal and that only small, early‑phase human studies are underway — the Annals of Oncology analysis and systematic searches identified just one active clinical trial of ivermectin in cancer and warned against conflating internet enthusiasm with clinical evidence — thus clinicians counsel caution and trial enrollment rather than off‑label use outside research ^{[3] [9] [10]}.

5. Competing narratives, incentives and the reporting problem

Reporting and advocacy sites amplify case compilations and single‑site initiatives that can create the impression of a growing clinical movement; industry‑style clinic pages or patient‑advocacy compilations frame low cost and wide availability as strengths, while mainstream oncology reviews highlight the ethical risk of patients forgoing proven therapies and the need for rigorous randomized data — readers should note these different incentives when interpreting claims about “recruiting trials” ^{[8] [10] [9]}.

6. Practical takeaway and limits of the current review

The current evidence base from the reviewed sources supports naming one actively recruiting, registered study of ivermectin in combination with immunotherapy for metastatic TNBC (NCT05318469) and finds no comparable registered, recruiting chemotherapy‑combination trials for fenbendazole; this assessment is limited to the cited reporting and registry summaries and does not substitute for a fresh ClinicalTrials.gov search or institutional trial listings, which could identify site‑level or newly posted studies not covered in these sources ^{[1] [2] [3] [6]}.